Baclofen for alcohol withdrawal: a placebo-controlled randomized multiple dose study

Terug naar alle onderzoeken

Samenvatting

Alcohol-use disorder is a major public health issue. The current gold standard for the prevention and treatment of the alcohol withdrawal syndrome is diazepam, a GABA-A agonist. Because of side effects like high sedation, risk of respiratory depression, addictive properties and liver impairment, an alternative pharmacological treatment option is desirable. Baclofen is a GABA-B agonist, prescribed for the treatment of spasticity. More recently, it’s off label use has found its place in the management of alcohol-use disorder because of its anti-craving properties. Given its effects on the GABA system and it lacking the negative aspects of diazepam, baclofen could be a viable treatment alternative in managing alcohol withdrawal. This controlled study investigates two dose levels of baclofen (30 and 60 mg/day) compared to diazepam in patients seeking treatment for alcohol withdrawal.

Contact

UZ Brussel, afdeling Psychiatrie
Dr. Cleo L. Crunelle

Algemene info

Looptijd

Startdatum 01/01/2016
Einddatum 01/01/2021

Methode

RCT

Type

Longitudinaal onderzoek

Gefinancierd door

Eigen middelen (los van subsidies)

Product

Alcohol

Discipline

Medische en farmacologisch onderzoek

Regio

Belgisch

Status

Lopend

Datum laatste wijziging: 10/04/2019
Dit item aanpassen